Skip to main content
Clinical Trials/NCT07762742
NCT07762742Not yet recruitingNot Applicable

A Comparative Study of Percutaneous Pulsed Field Ablation Guided by Ultrasound Alone Versus Fluoroscopy in Patients With Atrial Fibrillation

China National Center for Cardiovascular Diseases0 sites276 target enrollmentStarted: August 15, 2026Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
276
Primary Endpoint
Success rate of complete electrical isolation of pulmonary veins during the procedure

Study Overview

Brief Summary

This prospective, randomized, multicenter, open-label, non-inferiority interventional study aims to compare the therapeutic efficacy of percutaneous pulsed field ablation (PFA) guided by ultrasound alone versus fluoroscopy in patients with paroxysmal atrial fibrillation (AF). The success rate of complete electrical isolation of pulmonary veins during the procedure was compared to verify that ultrasound-only guidance is non-inferior to fluoroscopic guidance.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Adult patients aged 18 to 75 years (including 18 years and 75 years of age).
  • •Patients diagnosed with paroxysmal atrial fibrillation via 12-lead electrocardiography or ambulatory electrocardiography and scheduled to undergo pulsed field ablation.
  • •Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program.

Exclusion Criteria

  • •Atrial fibrillation secondary to electrolyte imbalance, thyroid disorders, or reversible non-cardiac causes;
  • •Previous history of catheter ablation or cardiac surgery for atrial fibrillation;
  • •Prior surgical history including patent foramen ovale closure, atrial septal defect closure or repair;
  • •Implantation of left atrial appendage occluder, mechanical mitral valve prosthesis, or valvuloplasty ring containing metallic materials;
  • •Concomitant other tachyarrhythmias requiring catheter ablation (e.g., atrioventricular reentrant tachycardia, atrioventricular nodal reentrant tachycardia, atrial tachycardia, atrial flutter, Wolff-Parkinson-White syndrome, etc.);
  • •Persistent atrial fibrillation;
  • •Left atrial anteroposterior diameter (LAD) > 55 mm on transthoracic echocardiography;
  • •Women who are pregnant, breastfeeding, or of childbearing age with plans to become pregnant during the clinical trial;
  • •Current participation in another pharmaceutical or medical device clinical study.

Arms & Interventions

Percutaneous pulsed field ablation performed under ultrasound-only guidance.

Experimental

Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation.

Intervention: Percutaneous pulsed field ablation is performed under ultrasound-only guidance in patients with paroxysmal atrial fibrillation. (Procedure)

Pulsed field ablation performed under fluoroscopic guidance

Active Comparator

Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance.

Intervention: Patients with paroxysmal atrial fibrillation underwent percutaneous pulsed field ablation under fluoroscopic guidance. (Procedure)

Outcomes

Primary Outcomes

Success rate of complete electrical isolation of pulmonary veins during the procedure

Time Frame: Immediately post-procedure

The proportion of all pulmonary veins maintaining bidirectional block across ablation lines at 20 minutes after ablation completion.

Secondary Outcomes

  • Compare the procedural time and DSA fluoroscopy time between the two groups.(Immediately post-procedure)
  • The incidence of complications within 30 days after the procedure(Within 30 days post-procedure)
  • Success rate of atrial fibrillation ablation at 12 months post-procedure.(12 months post-procedure)
  • The proportion of patients admitted to hospital or emergency departments due to atrial fibrillation recurrence within 12 months after the procedure.(12 months post-procedure)
  • The proportion of patients who received electrical cardioversion due to atrial fibrillation recurrence within 12 months after the procedure(12 months post-procedure)
  • The proportion of patients undergoing repeat ablation surgery owing to atrial fibrillation within 12 months after the procedure(12 months post-procedure)
  • The proportion of patients who resumed antiarrhythmic drug therapy during follow-up after the blanking period(From the end of the blanking period (within 90 days after catheter ablation) to 12 months post-procedure)
  • Improvement in the total EQ-5D quality-of-life questionnaire score at 12 months post-procedure compared with baseline(12 months post-procedure)
  • Statistical analysis was performed to evaluate differences in fluoroscopic exposure dose between the two groups.(Immediately post-procedure)
  • Compare the length of hospital stay and postprocedural ICU/CCU stay duration between the two groups.(through study completion, an average of 1 year)
  • Compare the differences in costs between the two groups, including medical equipment costs, personnel costs, and patient hospitalization expenses.(through study completion, an average of 1 year)

Investigators

Sponsor
China National Center for Cardiovascular Diseases
Sponsor Class
Other Gov
Responsible Party
Sponsor

Similar Trials